Tolfenamic acid (TA) is a non-steroidal anti-inflammatory drug associated with anti-tumorigenic and pro-apoptotic properties in animal and in vitro models of cancer. However, the underlying cellular mechanisms by which TA exerts its effects are only partially understood. Activating transcription factor 3 (ATF3) is a member of the ATF/CREB subfamily of the basic region-leucine zipper family and has been known as a tumor suppressor in human colorectal cancer cells. The present study was performed to observe whether ATF3 mediates TA-induced apoptosis and to elucidate the molecular mechanism of ATF3 transcription induced by TA. TA treatment and ectopic expression of ATF3 increased apoptosis, whereas knockdown of ATF3 resulted in significant repression of TA-activated apoptosis. The TA treatment also induced ATF3 promoter activity. Internal deletion and point mutation of the predicted ATF/ C/EBP binding site in ATF3 promoter abolished luciferase activation by TA. Overexpression of ATF2 resulted in significant increase in ATF3 promoter activity, and electrophoretic mobility shift assay identified this region as a core sequence to which ATF2 binds. TA treatment resulted in an increase in ATF2 phosphorylation, which was followed by a subsequent increase in ATF3 transcription. Knock down of ATF2 abolished TA-induced ATF3 expression. We further provide evidence that TA leads to increases in phospho-p38 MAPK, JNK and ERK levels. Inhibition of these pathways using selective inhibitors and dominant negative constructs ameliorated TA-induced ATF3 expression and promoter activities. The current study shows that TA stimulates ATF3 expression and subsequently induces apoptosis. These pathways are mediated through phosphorylation of ATF2, which is mediated by p38 MAPK-, JNK-and ERK-dependent pathways.
Introduction
Colorectal cancer is an important public health problem in the Western world (Parkin et al., 2005) and the third leading cause of cancer-related death in the United States (Jemal et al., 2009) . Chemoprevention by nonsteroidal anti-inflammatory drugs (NSAIDs) has received much attention as a very attractive and promising strategy. A number of studies have shown an inverse relationship between the consumption of NSAIDs and colorectal cancer (Gupta and Dubois, 2001) , and thus, molecular mechanisms by which NSAIDs affect chemopreventive activity in human colorectal cancer need to be elucidated.
Tolfenamic acid (TA) is a N-(2-methyl-3-chlorophenyl)-anthranilic acid that shows a pharmacological profile characteristic of NSAIDs. TA has been broadly used for migraines and has shown fewer side effects than other NSAIDs in the upper gastrointestine (Hansen, 1994) . The first study of TA's anti-cancer activity was performed in a pancreatic cancer model (Abdelrahim et al., 2006) . TA treatment inhibited metastasis and tumorigenesis through suppression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR1; Abdelrahim et al., 2006 Abdelrahim et al., , 2007 . Using human colorectal cancer cells, our group observed that TA stimulates apoptosis and upregulates the pro-apoptotic protein, early growth response-1, through epithelial-specific Ets-1-dependent transcriptional regulation . These data indicate that TA suppresses tumorigenesis by targeting various molecular mechanisms. Because the underlying cellular mechanisms, by which TA exerts its effects, are only partially understood, the molecular basis of apoptosis induction and the scope of its action in colorectal cancer need to be elucidated.
Activating transcription factor 3 (ATF3) is an ATF/ CREB subfamily member, which is characterized by containing the basic region-leucine zipper DNA binding domain (Hai et al., 1988) . ATF3 has diverse biological roles and the expression of ATF3 is dramatically upregulated in response to a variety of stress conditions in many different tissues (Hai and Hartman, 2001) . ATF3 is rapidly induced in cells treated with growthstimulating factors such as serum and growth factor (Iyer et al., 1999) . ATF3 enhances DNA synthesis in hepatocytes (Allan et al., 2001) and is involved in seruminduced cell proliferation as a target gene of c-myc (Tamura et al., 2005) . However, ATF3 has a dichotomous role in cancer development and it is likely that pro-or anti-apoptotic mechanism of ATF3 is dependent on cell or tissue context (Yin et al., 2008; Miyazaki et al., 2009) . The expression of ATF3 was repressed in human colorectal tumors compared with normal adjacent tissue (Bottone et al., 2004) . Ectopic expression of ATF3 induced apoptosis and suppressed growth of colorectal cancer cells (Fan et al., 2002) as well as Ras-stimulated tumorigenesis (Lu et al., 2006) . In previous studies, our group reported that ATF3 was induced by treatment with antitumorigenic compounds, including indole-3-carbinol (Lee et al., 2005) , conjugated linoleic acid , epicatechin (Baek et al., 2004; Cho et al., 2007) , berberine (Piyanuch et al., 2007) and phosphoinositide 3-kinase inhibitor . ATF3 expression is influenced by various cell signaling and transcription factors. ATF3 is a key mediator of Kru¨ppel-like factor 6-induced apoptosis in prostate cancer cells and mediates cyclooxygenase inhibitor-stimulated anti-invasive activity in human colorectal cancer (Bottone et al., 2005) . ATF3 directly enhances p53 activation (Yan et al., 2005) and stabilize p53 protein (Yan and Boyd, 2006) , as well as downregulates cyclin D1 (Lu et al., 2006) and matrix metalloproteinase-2 expression (Chen and Wang, 2004) . ATF3 also has a crucial role in REIC/Dkk-3-induced apoptosis and downregulation of inhibition of differentiation-1. (Kashiwakura et al., 2008) . Overexpression of ATF3 prolonged the half-life of p73 by inhibiting its ubiquitination and thereby enhancing its transactivation and proapoptotic activities (Oh et al., 2008) . ATF3 suppresses toll-like receptor-mediated pathways (Whitmore et al., 2007) and directly represses nuclear factor erythroid-derived 2-related factor 2 pathways (Brown et al., 2008) . Thus, overexpression of ATF3 negatively regulates tumorigenic pathways through multiple mechanisms, although there are contradictory results in the literature.
In the present study, we investigated the transcriptional mechanism and biological significance of ATF3 expression in response to TA-activated apoptosis in human colorectal cancer model. Here, we report that ATF2 acts as a mediator in the activation of the ATF3 gene by TA via MAPK-dependent pathways.
Results
TA induced ATF3 expression in human colorectal cancer and other cancer cells A number of studies indicate that NSAIDs prevent or suppress tumor development in human colorectal cancer (Gupta and Dubois, 2001) . To observe which NSAIDs induce ATF3 expression, we treated HCT-116 cells for 24 h with 30 mM of various NSAIDs: conventional (diclofenac, ibuprofen, aspirin, TA and naproxen) and COX-2 selective (SC-236, DFU, celecoxib) or COX-1 selective (SC-560). As a result, TA and celecoxib increased ATF3 expression (Figure 1a ). Sulindac sulfide also increased ATF3 expression in these cells (data not shown). The level of ATF3 protein dramatically increased in the cells treated with 20 mM TA for 24 h, and ATF3 mRNA increased in a dose-dependent manner (Figure 1b) . We also tested ATF3 expression in other colorectal cancer cells (Figures 1c and d) . The increased ATF3 expression was observed in HT-29, LoVo and SW480 cells in different concentrations, indicating that ATF3 induction by TA is observed in other colorectal cancer cells. TA also induced ATF3 expression in lung (A549) and prostate (PC-3) cancer cells, but not in breast (MCF-7), and head and neck (Spccy1) cancer cells. It is notable that basal expression of ATF3 is very high in Spccy1 cells.
ATF3-mediated TA-induced apoptosis
Previously, we reported that human colorectal cancer cells treated with TA increased apoptosis in a dosedependent manner . To see whether ATF3 expression affects apoptosis, enzyme activity of caspase 3/7 was measured in empty-or ATF3-expression vector (pCG-ATF3)-transfected cells. As shown in Figure 2a , overexpression of ATF3 increased caspase 3/7 activity, indicating that ATF3 is one of pivotal genes in the pathway of apoptosis. Next, to investigate whether TA-induced apoptosis is associated with ATF3 expression, the cells were transfected with ATF3 small interfering RNA, and poly (ADP-ribose) polymerase cleavage ( Figure 2b ) and caspase activity ( Figure 2c) were measured. As a result, knock down of ATF3 significantly suppressed poly (ADP-ribose) polymerase cleavage and enzyme activity, suggesting that ATF3 at least partially has a significant role in apoptosis induced by TA.
Effect of TA on ATF3 gene promoter activity To investigate whether TA affects transcriptional regulation of the ATF3 gene, promoter activity was measured using five serial deletion constructs (pATF3À1850/ þ 34, pATF3À1420/ þ 34, pATF3À718/ þ 34, pATF3À514/ þ 34 and pATF3À84/ þ 34) (Cai et al., 2000) . The promoters were transfected into HCT-116 cells and treated with 30 mM of TA for 24h. As shown in Figure 3a , TA treatment resulted in a dramatic increase in promoter activity, and fold inductions of luciferase activities were 7.7, 6.1, 6.2, 6.9 and 4.8 in pATF3 À1850/ þ 34-, pATF3À1420/ þ 34-, pATF3À718/ þ 34-, pATF3À514/ þ 34-and pATF3À84/ þ 34-transfected cells, respectively, whereas fold induction of luciferase in empty vector-transfected cells was 1.4. These data indicate that the À84 and þ 34 region of promoter is responsible for TA's effects. To identify potential regulatory cis-acting elements that mediate the stimulatory effects of TA, the TFSEARCH program (http:// molsun1.cbrc.aist.go.jp/research/db/TFSEARCH.html) was used to search for the regions of conserved transcription factor-binding site within the À84 and þ 34 regions. The ATF3 gene promoter (pATF3À84/ þ 34) contained multiple potential transcription factorbinding sites including IL-6, DTF-1, GCN-4, Sp1, Yi, GATA, ATF/C/EBP and CBFA-1 (Figure 3b , upper Figure 2 Role of ATF3 expression in TA-induced apoptosis. (a) pCG-ATF3 expression vector was transfected into cells using lipofectamine and then the cells were treated with 30 mM of TA for 24 h. Caspase 3/7 enzyme activity was measured as described in Materials and methods. The graph represents three independent experiments. (b) HCT-116 cells were transfected with control (cont) small interfering RNA (siRNA; 100 nM) or ATF3 siRNA (siATF3; 100 nM) for 24 h using a TransIT-TKO transfection reagent and then treated with 30 mM of TA for 24 h. Western blot analysis was performed for ATF3, poly (ADP-ribose) polymerase (PARP), and actin (upper panel). Data from three independent experiments were densitometrically analyzed using Scion Image (Scion Corp.) and cleaved PARP versus actin was quantified and expressed as fold induction (lower panel). (c) After transfection with control or ATF3 siRNA as described in (b), caspase 3/7 enzyme activity was measured. The data represent mean ± s.d. from three independent experiments.
Tolfenamic acid and ATF3 in human colorectal cancer S-H Lee et al panel). To confirm the responsible site for the transactivation of ATF3 gene by TA, we constructed eight deletion clones lacking each binding site. HCT-116 cells were transfected with deletion constructs and then exposed to dimethyl sulfoxide or TA for 24 h, and subsequently luciferase activity measured. As shown in Figure 3b (lower panel), transfection of wild-type pATF3À84/ þ 34 promoter increased luciferase activity by 5.2-fold, whereas transfection of promoter lacking the ATF/C/EBP-binding site increased luciferase activity by 1.2-fold, which is the same with basal induction by TA found in cells transfected with empty vector (pGL3-basic). Internal deletion of IL-6-, Sp1-, Yi-and CBFA-1-binding sites slightly increased the luciferase activity induced by TA. Other deletion constructs did not block TA-induced luciferase activities.
To obtain further evidence that the ATF/C/EBPbinding site is responsible for activation of ATF3 transcription by TA, we constructed three point mutation clones replacing two or three nucleotides within the ATF/C/EBP-binding site as described in Figure 3c . Wild-type pATF3À84/ þ 34 resulted in 4.7-fold induction of luciferase activity. However, all clones having point mutations in the ATF/C/EBP-binding site completely blocked the induction of luciferase activity by TA, which is comparable to empty vector-transfected cells. These results indicate that the region spanning À23 and À16 in the promoter of ATF3 has an essential role in mediating the effect of TA on ATF3 transactivation.
ATF2-mediated ATF3 promoter activation by TA ATF and C/EBP proteins have highly conserved DNAbinding domain and share their binding sites. The sequence of the C/EBP-binding oligonucleotide (TGAT GCAA) closely resembles the consensus sequence of CREB (TCACGTCA) and ATF2/3 (TGACGT (C/A)(G/A)). To investigate which transcription factor is able to affect ATF3 transcription, we measured ATF3 promoter activity after co-transfecting expression vectors including CREB, ATF2, ATF3, C/EBPa, C/EBPd, C/EBPb, CHOP (C/EBPz), GATA5 and NF-IL3. These proteins are able to bind to TGATGCAA site to some extent. Expression of transfected vectors was confirmed by western blot analysis (data not shown). As shown in Figure 4a , ATF2 expression caused a dramatic increase in TA-induced luciferase activity, compared with empty vector-transfected cells. Interestingly, expression of CREB, ATF3, C/EBPs and GATA5 significantly decreased TA-induced ATF3 promoter activation, implying that these transcription factors may function as suppressors of the ATF3 gene. ATF2-induced activation of ATF3 promoter activity was completely abolished in the presence of a construct lacking the ATF/C/EBP (À23 to À16), suggesting that ATF2 is necessary for the activation of the ATF3 promoter induced by TA (Figure 4b ).
ATF2 bound to the putative ATF/C/EBP-binding site in the ATF3 promoter region To examine whether transactivation of the ATF3 gene promoter by the ATF/C/EBP-binding site is direct or indirect, we performed electrophoretic mobility shift assays (EMSA) using oligonucleotide probes derived from the ATF3 promoter (À23 to À16). As shown in Figure 5a , TA caused an induction of formation of the DNA-protein complex. Pre-incubation of nuclear extracts with 10 Â or 100 Â excess unlabeled oligonucleotide abolished the binding activity (Figure 5b , lanes 3 and 4) suggesting that the binding protein is sequence Tolfenamic acid and ATF3 in human colorectal cancer S-H Lee et al specific. To identify the binding protein, supershift assay was performed using the antibody against ATF2 and phospho-ATF2. Pre-incubation of nuclear extracts with a phospho-ATF2-specific antibody resulted in reduction of the protein-DNA complexes, whereas antibody for immunoglobulin G and ATF2 did not affect the DNAprotein complex, suggesting that the binding protein is phospho-ATF2 (Figure 5c ).
TA induced phosphorylation of ATF2, and knock down of ATF2 decreased TA-induced ATF3 expression Phosphorylation of ATF2 has been shown to be crucial to its ability to bind to cognate DNA sequences and activate gene transcription. Thus, we determined whether TA affects phosphorylation of ATF2. As shown in Figure 6a , phospho-ATF2 started to increase at 15 min and reached a maximum at 30 min after TA treatment. The induction of ATF2 phosphorylation was followed by high induction of ATF3 after the TA treatment. ATF3 mRNA levels started to increase at 1 h and showed a time-dependent increase ( Figure 6b ). To observe the role of ATF2 in TAinduced ATF3 expression, the cells were transfected with control or ATF2 small interfering RNA, and ATF3 expression was measured. As shown in Figure 6c , knock down of ATF2 significantly ameliorated ATF3 expression by TA, confirming that ATF2 mediates TA-induced ATF3 expression.
Phosphorylation of ATF2 and ATF3 expression was mediated by MAPK pathways MAPK signaling is an important pathway affecting ATF2 phosphorylation (Ouwens et al., 2002) . So, we examined whether TA treatment affects MAPK pathways. As shown in Figure 7a , TA enhanced phosphorylation of ERK, JNK and p38MAPK proteins. To investigate whether these kinases affect TA-induced ATF3 expression, HCT-116 cells were pre-treated with selective inhibitors for p38MAPK, ERK and JNK, and treated with dimethyl sulfoxide and 30 mM of TA. As shown in Figures 7b-d , in the presence of inhibitors against p38MAPK (SB203580), ERK (U0126 and PD98059) or JNK kinase (SP600125), TA-induced phosphorylation of ATF2 and expression of ATF3 was inhibited. To confirm the ERK and p38MAPK dependency of ATF3 expression, we transfected wild type or dominant negative constructs of ERK2 and p38 MAPK, and compared TA-induced ATF3 expression. As shown in Figure 7e , TA-activated ATF3 expression was blocked in the presence of dominant negative kinases of ERK2 and p38. In addition, pre-treatment with inhibitors of ERK, p38MAPK and JNK suppressed the ATF3 promoter activity (Figure 7f ). Overall, three major MAPK pathways implicated in the TA-induced phosphorylation of ATF2.
Discussion
The anti-tumorigenic effects of TA in recent studies have raised an important question regarding the underlying molecular mechanisms. Here, we show direct evidence that TA enhances apoptosis of human colorectal cancer cells through activation of ATF3 gene transcription via ATF2 phosphorylation in human colorectal cancer cells. ATF3 markedly accelerated TA-induced apoptosis and knock down of ATF3 expression ameliorates TA-induced apoptosis (Figure 2 ). These data indicate significant relevance of ATF3 gene expression to TA-mediated cancer suppression and a contributory role of ATF3 in caspase 3-and 7-mediated pathways. Nuclear extract protein from TAtreated cells was preincubated with a 10-or 100-fold excess of unlabeled oligonucleotide for 10 min and then incubated with biotinlabeled oligonucleotide and 1 Â binding buffer (Promega) at room temperature for 20 min. (c) NE protein was preincubated with specific antibodies (Ab) against immunoglobulin (Ig) G, phospho-ATF2 or ATF2 for 10 min and then incubated with labeled oligonucleotide and 1 Â binding buffer (Promega) at room temperature for 20 min. DNA-protein complexes were resolved by 5% non-denaturing polyacrylamide gel and developed using the protocol of LightShift Chemiluminescent electrophoretic mobility shift assays kit (Pierce).
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Internal deletion and point mutation of the ATF/C/ EBP-binding site (À23/À16) in the upstream regulatory region of the ATF3 promoter completely blocked the ability of TA to stimulate promoter activity, suggesting that proteins bound to this site mediate the ability of TA to stimulate ATF3 promoter activity. EMSA data showed that phospho-ATF2 is present in complexes bound to the ATF/C/EBP-binding site in the ATF3 promoter and this binding is increased by TA. Furthermore, overexpression of ATF2 activates the ability of TA to stimulate gene expression via ATF3 transactivation. On the contrary, knock down of ATF2 ameliorated TA-induced ATF3 expression. This study indicates that ATF2 directly regulates ATF3 gene expression induced by TA.
ATF2, another member of the ATF/CREB family of basic region-leucine zipper protein, has an important role in the cellular stress response (Maekawa et al., 1989) . ATF2 expression has been associated with the maintenance of cancer cell phenotype. ATF2 directly targets genes such as c-jun, cyclins, TNFa, TGFb and DNA polymerase b, which are known to have important roles in the stress response, immune response, cell growth and differentiation (Bhoumik and Ronai, 2008) . However, other studies show anti-proliferative or apoptotic role of ATF2. Heterozygous Atf2 mutant mice are highly prone to mammary tumors (Maekawa et al., 2007) , and ATF2 has significant role in hypoxiainduced apoptosis and suppresses the development of mammary tumors (Maekawa et al., 2007) . Suppression of mammary tumors by ATF2 is associated with the activation of tumor suppressor genes Maspin and GADD45a (Maekawa et al., 2008) . In keratinocytes, the loss of ATF2 promotes the tumor formation, suggesting a tumor suppressor role of ATF2 in skin . Genetic variants of the ATF2 gene were also detected in 5 of the 46 (10.6%) lung cancers (Woo et al., 2002) . Further, constitutively nuclear-localized ATF2 suppressed ionizing radiationinduced prostate cancer progression (Deng et al., 2008) . So far, the biological effect of ATF2 expression has not been studied in colorectal cancer models. Although ATF2 expression did not affect apoptosis directly in human colorectal cancer cells (data not shown), it is likely that phosphorylation of ATF2 contributes to the enhancement of apoptosis via activation of their target genes such as ATF3. Likewise, activation of signal transduction pathways by TA treatment may result in the phosphorylation of ATF2 and regulation of its activity as suggested previously. In fact, the promising anticancer agent 3,3 0 -di-indolylmethane activates both JNK and p38 pathways, resulting in ATF2 phosphorylation (Xue et al., 2005) . Thus, selection of the target gene, apoptotic or antiapoptotic, depends on the type of stress signal and the presence of other binding partners.
Interestingly, protein level of ATF2 was abruptly increased at an early time point after TA treatment (Figure 6a ). It is likely that the increase in total protein of ATF2 is associated with its phosphorylation because phosphorylation of ATF2 protects ATF2 from ubiquitination and subsequent degradation (Fuchs et al., 2000) .
This study also indicated that TA treatment not only caused activation of p38MAPK and JNK, but also increased phosphorylation of ERK. Although we did not examine the changes of ATF2 Thr 69 in this study, it has been shown that p38MAPK phosphorylates ATF2 on Thr 69 and Thr 71 residues. The ability of ATF2 to bind to cognate DNA sequence and activate its target gene depends on the phosphorylation of ATF2. The current data show that phosphorylation of ATF2 by TA is positively regulated by the p38MAPK, ERK and JNK pathways, which subsequently modulate transcriptional activity of ATF3. This highlights a new role for the kinase pathways in the control of cell growth and apoptosis initiated by TA.
One interesting finding of this study is that overexpression of ATF3, all C/EBPs, CREB and GATA5 suppressed TA-induced ATF3 transactivation (Figure 4a ). This is consistent with data that ATF3 auto-represses itself transcriptionally through the same ATF-binding site we indicated (Wolfgang et al., 2000) . Although it is unclear how those transcription factors repress ATF3 transactivation, we may speculate that activation of ATF2 by phosphorylation sequesters inhibitory promoter activity by other basic regionleucine zipper proteins.
In conclusion, the current study provides information on the molecular mechanism of anti-tumorigenic activity by TA. MAPK pathways influence TA-induced phosphorylation of ATF2 and subsequently activate ATF3 expression. The resulting ATF3 activation induces apoptosis in human colon cancer cells (Figure 7g ).
Materials and methods

Materials
Human cancer cell lines (HCT-116, HT-29, LoVo and SW480) and other cancer cell lines (A549, MCF-7, PC-3 and Spccy1) were purchased from American Type Culture Collection (Manassas, VA, USA). The following culture media were purchased: McCoy's 5A (Bio Whittaker, Rockland, ME, USA), RPMI1640 (Mediatech, Herndon, VA, USA), Ham's F-12 (HyClone, Logan, UT, USA) and Dulbecco's modied Eagle 0 s medium (Invitrogen, Carlsbad, CA, USA). TA was purchased from Cayman Chemical (Ann Arbor, MI, USA), and SB203580, U0126, PD98059 and SP600125 were purchased from Calbiochem (San Diego, CA, USA). Antibodies for ATF3, ATF2, phospho-ERK, ERK and actin, and small interfering RNA for ATF3 and ATF2 were purchased from Santa Cruz (Santa Cruz, CA, USA). Antibodies for poly (ADP-ribose) polymerase, phospho-JNK, JNK, phosphop38MAPK, p38MAPK and phospho-ATF2 (Thr71) were purchased from Cell Signaling (Beverly, MA, USA). All chemicals were purchased from Fisher Scientific (Pittsburgh, PA, USA), unless otherwise specified.
Cell culture HCT-116 and HT-29 cells were maintained in McCoy's 5A medium. SW480 cells were maintained in RPMI1640. LoVo, A549 and PC-3 cells were maintained in Ham's F-12. MCF-7 and Spccy1 cells were maintained in Dulbecco 0 s modied Eagle 0 s medium. All culture media were supplemented with 10% fetal bovine serum, 100 units per ml penicillin, and 100 mg per ml streptomycin.
Promoters
Human ATF3 promoter constructs (pATF3À1850/ þ 34 and pATF3À84/ þ 34) were generously provided by Dr S Kitajima (Tokyo Medical and Dental University, Tokyo, Japan) and pATF3À1420/ þ 34, pATF3À718/ þ 34 and pATF3À514/ þ 34 were produced from pATF3À1850/ þ 34 using serial deletion . The internal deletion or point mutation constructs of the ATF3 promoter were constructed from wildtype pATF3À84/ þ 34 using the QuikChange II mutagenesis kit (Stratagene, La Jolla, CA, USA) with indicated primers (Table 1) .
Expression vectors
Full-length C/EBPa, C/EBPd, CHOP, GATA5 and NF-IL3 cDNAs were amplified from human lung cDNA (Clontech, Mountain View, CA, USA) using ReadyMix Taq polymerase (Sigma, St Louis, MO, USA) with indicated primers (Table 2) . PCR was performed for 30 cycles at 94 1C for 1 min, 55 1C for 1 min and 72 1C for 2 min. PCR product of C/EBPa, C/EBPd, CHOP, GATA5 and NF-IL3 were sub-cloned into pcDNA3.1/ V5/His TOPO vector (Invitrogen) to generate the V5-Histagged clones. For C/EBPb-expression vector, pOTB7 vector containing full-length C/EBPb cDNA (Open Biosystems, Huntsville, AL, USA) were digested using EcoRI and Xho I and sub-cloned into pcDNA3.1 (Invitrogen) to generate pcDNA3.1/C/EBPb. The pCG-ATF3 expression construct was generously provided by Dr T Hai (Ohio State University, Columbus, OH, USA). The ATF2-expression vector (pEBG2T-GST-ATF2-6His) and CREB-expression vector were kindly provided by Dr Philip Cohen (University of Dundee, Scotland, UK) and Dr Joo-Heon Yoon (Yonsei University, Seoul, Korea), respectively. The wild type and dominant negative construct of ERK2 were kindly provided by Dr Melanie Cobb (University of Texas Southwestern, Dallas, TX, USA). The wild type and dominant negative construct of p38 MAPK was previously described (Hao et al., 2007) .
Caspase 3/7 enzyme activity Enzyme activity of capsapse 3/7 was analyzed using Apo-ONE Homogeneous Caspase-Glo 3/7 Assay kit (Promega, Madison, WI, USA) according to the manufacturer's protocol. The cells were harvested with radioimmunoprecipitation assay buffer containing protease inhibitors, and the same volume of caspase-Glo 3/7 reagent was added to the cell lysates (50 mg protein) in 96-well plates and incubated at room temperature in the dark for 1 h. The luminescence was measured using a FLX800 microplate reader (BioTek, Winooski, VT, USA).
Transient transfections
Transient transfections were performed using Lipofectamine (Invitrogen) according to the manufacturer's instruction. HCT-116 cells were plated in 12-well plates at the concentration of 2 Â 10 5 cells/well. The next day, plasmid mixtures containing 0.5 mg of ATF3 promoter linked to luciferase and 0.05 mg of pRL-null vector were transfected for 5 h and cells were incubated with fresh media for 24 h. The transfected cells Table 1 Primer sequence for internal deletion or point mutation clones of ATF3 promoters
Forward Reverse
Internal deletion DIL-6 5 0 -GTAAGCTTGCAACACGGAGTAAACGACCGC-3
Abbreviation: ATF3, activating transcription factor 3. 
Tolfenamic acid and ATF3 in human colorectal cancer S-H Lee et al were exposed to dimethyl sulfoxide or 30 mM of TA for 24 h. The cells were harvested in 1 Â luciferase lysis buffer and luciferase activity was normalized to the pRL-null luciferase activity using a dual luciferase assay kit (Promega). For the cotransfection experiment, 0.25 mg of ATF3 promoter and 0.25 mg of expression vectors were co-transfected with 0.05 mg of pRL-null vector as described above.
Isolation of RNA and semi-quantitative reverse transcriptase PCR Total RNA was prepared using an RNA isolation kit (Eppendorf, Hamburg, Germany). Total RNA (1 mg) was reverse transcribed with the iScript cDNA kit (BioRad, Hercules, CA, USA) according to the manufacturer's instruction. PCR was carried out using ReadyMix Taq polymerase (Sigma) with primers for human ATF3 and glyceraldehyde 3-phosphate dehydrogenase as follows: ATF3: forward 5 0 -GTTTGAGGATTTTGCTAACCTGAC-3 0 and reverse 5 0 -AGCTGCAATCTTATTTCTTTCTCGT-3 0 , glyceraldehyde 3-phosphate dehydrogenase: forward 5 0 -GGGCTGCTTTTAAC TCTGGT-3 0 and reverse 5 0 -TGGCAGGTTTTTCTAGACGG-3 0 .
Western blot analysis Cells were washed with phosphate-buffered saline and cell lysates were isolated in radioimmunoprecipitation assay buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate and 0.1% SDS) supplemented with protease inhibitors (1 mM phenylmethanesulfonylfluoride, 5 mg per ml aprotinin and 5 mg per ml leupeptin) and phosphatase inhibitors (1 mM Na 3 VO 4 and 1 mM NaF), and centrifuged at 10 000 g for 5 min at 4 1C. Protein concentration was determined by the bicinchoninic acid protein assay (Pierce, Rockford, IL, USA) using bovine serum albumin as the standard. The proteins were separated on SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Osmonics, Minnetonka, MN, USA). The membranes were incubated with a specific primary antiserum in tris-buffered saline containing 0.05% Tween 20 and 5% non-fat dry milk at 4 1C overnight. After three washes with TBS-T, the blots were incubated with peroxidaseconjugated immunoglobulin G for 1 h at room temperature, visualized using ECL (Amersham Biosciences, Piscataway, NJ, USA) and quantified by Scion Image Software (Scion Corp., Frederick, MD, USA).
EMSA Nuclear extracts were prepared according to the manufacturer's protocols (Active Motif, Carlsbad, CA, USA). Oligonucleotide probes were end-labeled with biotin using the following sequences: 5 0 -AGGGGTGATGCAACGCTCTCA GGGGTGATGCAACGCTCTC-3 0 . ATF/C/EBP binding sites are underlined. Nuclear protein (5 mg) was incubated with biotinlabeled oligonucleotide probes (100 nM) and 1 Â binding buffer (Promega) at room temperature for 20 min. For competition assay, nuclear extracts were pre-incubated with the unlabeled oligonucleotide (10 Â or 100 Â ) for 10 min. For supershift assay, nuclear extracts were pre-incubated with antibodies for phospho-ATF2 or ATF2 for 10 min before binding reactions. DNAprotein complexes were resolved by 5% non-denaturing polyacrylamide gel and developed using the protocol of LightShift Chemiluminescent EMSA kit (Pierce).
Statistical analysis
Statistical analysis was performed with Student's unpaired t-test, with statistical significance set at *Po0.05; **Po0.01; ***Po0.001.
